The first patent, "Veto Cells Generated from Memory T Cells" (No. 10,961,504), covers Veto Cells generated from T cells that have been exposed to disease-related antigens that allow them to efficiently recognize and attack specific targets, including viruses, bacteria, and cancer. Veto Cells can be imbued with memory from third-party sources, making it a stand-alone approach.

The second patent, "Methods of Transplantation and Disease Treatment" (No. 10,933,124), covers the action of Veto Cells as companion cells that allow cellular therapies such as chimeric antigen receptor (CAR) T and natural killer (NK) to be safely tolerated by the patient without transplant rejection or graft versus host disease.

In this approach, a therapeutic amount of central memory T-lymphocyte phenotype (Tcm) anti-third-party Veto Cells are administered to the patient as "passport" or "bodyguard" cells for the purpose of inducing immune tolerance. The anti-third-party Veto Cells can be used as an adjuvant therapy in this case.

Humanigen awarded 2 patents against immunotherapy toxicities
The U.S. Patent and Trademark Office has awarded Humanigen two patents for the use of lenzilumab.

ERS Genomics licenses gene editing tech to G+FLAS
ERS Genomics has signed a nonexclusive licensing deal granting G+FLAS Life Sciences access to its CRISPR/Cas9 patent portfolio.

Precision BioSciences nabs patent for CAR construct tech
Precision BioSciences has received a notice of allowance from the U.S. Patent and Trademark Office for patent application, No. 16/908, 030. The patent...